ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
Pharmacokinetics of Extended-Release Meloxicam in Tufted Titmice (Baeolophus bicolor) Following Subcutaneous Administration.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Analgesic regimens for laboratory-housed avian species remain poorly defined, with limited pharmacokinetic data available, particularly in passerine birds. This study characterized the pharmacokinetics of extended-release (ER) meloxicam in tufted titmice (Baeolophus bicolor) following single subcutaneous dosages of 3 and 6 mg/kg. We hypothesized ER meloxicam would sustain therapeutic plasma concentrations (>3,500 ng/mL), previously established in zebra finches and larger avian species, for 72 hours. Pharmacokinetic analysis revealed significantly higher Cmax and faster clearance at 6 mg/kg compared with 3 mg/kg. Although therapeutic plasma levels (>3,500 ng/mL) were observed at 1 hour postadministration, concentrations decreased below previously established therapeutic thresholds by 4 hours postinjection at both dosages. Histopathologic examination revealed no significant drug-related adverse effects. These findings suggest subcutaneous administration of ER meloxicam at 3 and 6 mg/kg does not sufficiently prolong therapeutic analgesia in tufted titmice, with a shorter therapeutic duration of action than previous findings with intramuscular meloxicam in small passerines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.